Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
Open Access
- 8 October 2021
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 10 (000), 128-133
- https://doi.org/10.14218/jcth.2021.00200
Abstract
A new definition of metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed in 2020. The change from nonalcoholic fatty liver disease (NAFLD) to MAFLD highlights the metabolic abnormalities that accompany fatty liver. The diagnosis of MAFLD does not require exclusion of secondary causes of liver diseases and alcohol consumption. Thus, MAFLD may coexist with other types of liver diseases, such as viral hepatitis, a disease that remains the most common cause of liver disease-related death. With the increasing prevalence of MAFLD, patients with coincidental MAFLD and viral hepatitis are frequently encountered in clinical practice. In this review, we mainly summarize the mutual relationship between hepatitis B/C and systematic metabolism dysfunction related to MAFLD. We discuss the impact of MAFLD on progression of viral hepatitis and the therapies. Some unaddressed clinical problems related to concomitant MAFLD and viral hepatitis are also identified.Keywords
This publication has 77 references indexed in Scilit:
- Inverse Association between Hepatitis B Virus Infection and Fatty Liver Disease: A Large-Scale Study in Populations Seeking for Check-UpPLOS ONE, 2013
- Abnormalities of lipid metabolism in hepatitis C virus infectionGut, 2010
- Hepatitis C infection and risk of diabetes: A systematic review and meta-analysisJournal of Hepatology, 2008
- Suppression of p38 mitogen-activated protein kinase inhibits hepatitis B virus replication in human hepatoma cell: the antiviral role of nitric oxideJournal of Viral Hepatitis, 2008
- A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injuryJournal of Hepatology, 2007
- Impact of steatosis on progression of fibrosis in patients with mild hepatitis CJournal of Hepatology, 2004
- Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXRGenes & Development, 2004
- Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis CJournal of Hepatology, 2003
- Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infectionCancer, 2003
- Expression of liver steatosis in hepatitis C virus infection and pattern of response to α-interferonJournal of Hepatology, 2001